Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first...

Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center...

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma ( Dr Evan Jacob Lipson - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )

Rare inherited pathogenic germline variants observed in sporadic paediatric...

Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA

Rare inherited pathogenic germline variants observed in sporadic paediatric neuroblastoma cases ( Dr Emily Blauel - Children’s Hospital of Philadelphia, Philadelphia, USA )

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small...

Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France

PIPSeN trial: Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer ( Dr Sophie Postel-Vinay - Gustave Roussey Cancer Center, Paris, France )

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA...

Dr Matthew Marx - Mirati Therapeutics, San Diego, USA

MRTX9768: a synthetic lethal-based inhibitor designed to bind the PRMT5 MTA complex and target MTAP/CDKN2A-deleted tumours ( Dr Matthew Marx - Mirati Therapeutics, San Diego, USA )

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of acquired resistance to KRAS G12C inhibition in cancer ( Dr Mark Awad - Dana-Farber Cancer Institute, Boston, USA )

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients...

Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

Phase III randomised trial comparing tebentafusp with investigator’s choice in...

Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in...

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )

SMMART Program: A multi-omics tumour board with a focus on breast cancer

Dr Ben Kong - Oregon Health & Science University, Portland, USA

SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )

More from ecancer